GSK cancer drug combination approved

Share this article:
GSK cancer drug combination approved
GSK cancer drug combination approved

GlaxoSmithKline now has the first combination oral targeted therapy for unresectable metastatic melanoma with BRAF V600 or V600K mutation. The company announced Wednesday that the FDA approved using Mekinist (trametinib) and Tafinlar (darafenib) in tandem for the condition, and as a team approach to treat metastatic melanoma with either of these mutations.

The agency approved the drug combination based on using Phase I and Phase II data under the priority review program. The drugmaker is also set to deliver Phase III results from its Combi trial at a later date.

The approval moves documented off-label use of the drugs into officially sanctioned territory. However, it may require more than physician inclination to help the combined therapy take off. Kantar Health Director Gordon Gochenauer noted in the consulting firm's blog last fall that the National Comprehensive Cancer Network would have to agree to provide reimbursement because the combined drug therapy would drive up advanced melanoma treatments to about $16,000 a month, with a typical treatment lasting around a year.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.